Interactive tool
Compounded Ingredient Regulatory-Status Explorer
Approved alternatives; shortage; bulk-list status; monograph; investigational status; legal caveats; source dates.
This tool runs entirely in your browser against the same canonical datasets that drive the visible pages and the public downloads, so the tool and the pages cannot disagree. It reports what a named public record says on the date it was checked. It issues no badge, score, ranking, or safety verdict of any kind.
Key findings
- Primary focus: Approved alternatives.
- Registration with FDA is not FDA approval, and a state licence is not a quality assessment.
- Unverified fields render fail-closed; no badge, score, or ranking is generated from missing data.
- Current and historical records are separated and labelled distinctly.
- Named entities may respond to any record through the right-to-respond process.
| Approved alternatives | Verification Pending |
|---|---|
| Shortage | Verification Pending |
| Bulk-list status | Verification Pending |
| Monograph | Verification Pending |
| Investigational status | Verification Pending |
| Legal caveats | Verification Pending |
| Federal framework | License Verified FDA sources verified 2026-07-23 |
| Entity-specific data | Verification Pending |
Ingredient regulatory-status explorer
Regulatory position for each monitored substance, generated from the same records that drive the medication pages.
| Substance | Current regulatory position |
|---|---|
| Semaglutide Injection | Semaglutide injection shortage was resolved by FDA Declaratory Order on 21 February 2025. |
| Tirzepatide Injection | Tirzepatide was removed from the shortage list on 2 October 2024 and confirmed by Declaratory Order on 19 December 2024. |
| Liraglutide | Liraglutide was included in FDA's 30 April 2026 proposal to exclude it from the 503B bulks list. |
| Semaglutide B12 | Semaglutide injection shortage was resolved by FDA Declaratory Order on 21 February 2025. |
| Tirzepatide B12 | Tirzepatide was removed from the shortage list on 2 October 2024 and confirmed by Declaratory Order on 19 December 2024. |
| Semaglutide B6 | Semaglutide injection shortage was resolved by FDA Declaratory Order on 21 February 2025. |
| Tirzepatide Glycine | Tirzepatide was removed from the shortage list on 2 October 2024 and confirmed by Declaratory Order on 19 December 2024. |
| Semaglutide Oral Odt Sublingual | Oral semaglutide does have an approved form — Rybelsus — but it is a tablet using a specific absorption enhancer (SNAC) . |
| Tirzepatide Oral Odt Sublingual | There is no approved oral or sublingual tirzepatide in any form anywhere. |
| Mic B12 | MIC/B12 is a lipotropic combination of methionine, inositol and choline with cyanocobalamin. |
| L Carnitine | An FDA-approved product containing this active ingredient exists. |
| Glutathione | Glutathione is an endogenous antioxidant tripeptide of glutamate, cysteine and glycine, marketed for intravenous or intr. |
| Nad Plus | NAD+ is a coenzyme marketed for injection or infusion. |
| Sermorelin | Sermorelin acetate is a synthetic analogue of the first 29 amino acids of growth hormone releasing hormone. |
| Cjc1295 Ipamorelin | CJC-1295 and ipamorelin are growth hormone secretagogues frequently sold as a combined preparation. |
| Bpc 157 | BPC-157 is a synthetic pentadecapeptide derived from a gastric protein sequence. |
| Tb 500 | TB-500 is a synthetic fragment of thymosin beta-4. |
| Pt 141 | An FDA-approved product containing this active ingredient exists. |
| Testosterone Cypionate | An FDA-approved product containing this active ingredient exists. |
| Testosterone Creams | Compounded testosterone cream is a topical androgen preparation. |
| Estradiol Creams | Compounded estradiol cream is a topical estrogen preparation. |
| Progesterone Capsules | An FDA-approved product containing this active ingredient exists. |
| Dhea | Regulatory position for this preparation has not been established against a primary source at this snapshot.. |
| Low Dose Naltrexone | An FDA-approved product containing this active ingredient exists. |
| Ketamine | This is a controlled substance as well as a compounded preparation, so DEA registration and state controlled-substance r. |
| Sildenafil Troches | This is an altered dosage form. |
| Tadalafil Troches | This is an altered dosage form. |
| Finasteride Minoxidil | An FDA-approved product containing this active ingredient exists. |
| T4 T3 Thyroid | An FDA-approved product containing this active ingredient exists. |
| Topical Pain Creams | This is an altered dosage form. |
What a result from this tool means
What this means
- Compoundability depends on shortage listing, bulks-list position, and approved-product availability.
- The rules differ between 503A pharmacies and 503B outsourcing facilities.
- Positions change through rulemaking and are dated here.
What this does not mean
- That a substance being compoundable makes any specific product safe or effective.
- That this is legal advice for any particular arrangement.
- That a status shown today will hold tomorrow.
What this tool can and cannot settle
A lookup tool answers one question well and creates a temptation to over-read the answer. This one reports what a named public record says on the date it was captured. It does not assess, score, or certify anything, and a result is a starting point for verification rather than its conclusion.
The specific limit worth understanding: a snapshot is not a live query. FDA updates its outsourcing facility register weekly and state boards update continuously, so a result here confirms what the record said on the snapshot date and nothing about today. For anything consequential, go to the source register directly — every result links to it.
- Results reflect a dated snapshot, not a live query against the source register.
- FDA updates its outsourcing facility register weekly; state boards update continuously.
- Self-reported registration information on FDA's list has not been verified by FDA.
- Absence of a result is absence from this snapshot, not evidence that no record exists anywhere.
| Question | Can this tool answer it? | What actually answers it |
|---|---|---|
| Is this facility federally registered? | Yes, as of the snapshot date | FDA outsourcing facility register |
| Is its state licence current today? | No | The issuing state board's live register |
| Has it been inspected? | No | FDA inspection records |
| Were there Form 483 observations? | No | FDA inspection records |
| Is there an active warning letter? | No | FDA warning letter database |
| Is this pharmacy safe to use? | No — and no tool can | No public record answers this question |
Related records in this section
Section hub: Interactive tools · Methodology · Status definitions · Right to respond
Frequently asked questions
What does this page cover on can a drug be compounded?
Approved alternatives; shortage; bulk-list status; monograph; investigational status; legal caveats; source dates.
What is established about approved alternatives?
Approved alternatives is tracked as part of can a drug be compounded. The record holding it is named in the source map on this page, and its verification state is shown in the status snapshot rather than asserted in prose.
What is established about shortage?
shortage is tracked as part of can a drug be compounded. The record holding it is named in the source map on this page, and its verification state is shown in the status snapshot rather than asserted in prose.
What is established about bulk-list status?
bulk-list status is tracked as part of can a drug be compounded. The record holding it is named in the source map on this page, and its verification state is shown in the status snapshot rather than asserted in prose.
Where does this tool get its data on can a drug be compounded?
From the same canonical datasets that drive the visible pages and the public downloads, so the tool and the pages cannot disagree.
Sources
- FDA — Information for Outsourcing Facilities
- FDA — Q&A: Outsourcing Facility Registration
- FDA — Registered Outsourcing Facilities
- FDA — Aligning Federal and State Regulation of Compounders
- FDA — Outsourcing Facility Fees
- FDA — Compounded Drug Products That Are Essentially Copies
- FDA — Proposes to Exclude Semaglutide, Tirzepatide and Liraglutide from 503B Bulks List (30 Apr 2026)
- FDA — Registration of Human Drug Compounding Outsourcing Facilities (guidance)
- Nevada Board of Pharmacy — Notice of FDA Declaratory Orders (tirzepatide, semaglutide)
- FDA — Outsourcing Facility Fees guidance
Update history
| Date | Change |
|---|---|
| 2026-07-23 | Record published at current snapshot. |
Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.